drugset / Trial / NCT04294836

Curcumin in Advanced Cervical Cancer

NCT04294836

RandomizedParallel-groupDouble-blindTreatment

Summary

Determine the efficacy and safety of turmeric in the treatment of patients with advanced cervical cancer. Efficacy will be determined through radiological and histopathological criteria through the rate of response to treatment, duration of response, the rate of objective response and disease control, as well as overall survival and disease-free survival. The safety of therapy will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) classification

Timeline

Start
2021-12-01
Primary completion
2023-01-31
Completion
2023-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 500 mg Oral

Indications